ArticleCancer biology & therapy2015

Enzalutamide for treatment of CRPC: rationale for sequencing and potential clinical biomarker for resistance.

Sarah E Lochrin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.